Skip to content
2000
Volume 22, Issue 12
  • ISSN: 1871-5206
  • E-ISSN:

Abstract

Aims: The study aims to synthesize hybrid molecules containing pyrazole and aryldiazenyl/arylhydrazono fragments with promising anticancer activity. Background: The clinical effectiveness of anticancer drugs is limited by their adverse side effects and patient resistance. Therefore, the development of safer classes of drugs through rational drug design is imperative. Objective: Considering the anticancer potential of the pyrazole moiety, the study was carried out with the objective of synthesizing some hybrid pyrazole derivatives with anticancer potential. Methods: The anticancer potential of these pyrazolyl analogues were evaluated by sulforhodamine B assay using three cancer cell lines MCF-7, HepG2, and HCT-116. Results: HCT-116 was the most sensitive cell line against these pyrazolyl analogues. Among these newly synthesised derivatives, 1-(4-((4-bromophenyl)diazenyl)-3,5-dimethyl-1H-pyrazol-1-yl)-2-(naphthalen-2-yloxy)ethan-1-one (5e) emerged as a promising anticancer agent (IC 3.6-24.6 μM), having a xanthine oxidase inhibitory effect (IC 10.87 μM). To obtain further insights into the binding interactions of these molecules, molecular docking studies were also carried out. Conclusion: In summary, our findings suggest that these hybrid pyrazolyl derivatives can be considered as potential lead molecules for anticancer agents.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/1871520622666220110162651
2022-07-01
2024-11-07
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/1871520622666220110162651
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test